# Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

> **NCT06799637** · PHASE1,PHASE2 · RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Pancreatic Carcinoma
- Ovarian Cancer
- Cervical Cancers

## Interventions

- **DRUG:** XNW28012

## Key facts

- **NCT ID:** NCT06799637
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06799637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06799637, "Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06799637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*